Familial hypofibrinogenemia

Summary

Familial hypofibrinogenemia (MONDO:0015096) is a disease with 3 cohort genes. The dominant Reactome pathway is Aggregated β-amyloid interacts with fibrinogen (3 cohort genes).

At a glance

• Prevalence: Unknown (Worldwide)
• Cohort genes: 3
• Phenotypes (HPO): 4

Clinical features

Signs & symptoms

Clinical features (HPO)

4 HPO clinical features (Orphanet curated; top 4 by frequency):

HPO ID	Term	Frequency
HP:0000225	Gingival bleeding	Very frequent (80-99%)
HP:0000421	Epistaxis	Very frequent (80-99%)
HP:0001892	Abnormal bleeding	Very frequent (80-99%)
HP:0002239	Gastrointestinal hemorrhage	Very frequent (80-99%)

Identifiers

Disease identifiers

Field	Value
Canonical name	familial hypofibrinogenemia
Mondo ID	MONDO:0015096
Orphanet	101041
UMLS	C5681803
MedGen	1826143
GARD	0002887
Is cancer (heuristic)	no

Also known as: hypofibrinogenemia, familial

Data availability: 3 GenCC gene-disease records.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood coagulation disease › coagulation protein disease › congenital fibrinogen deficiency › familial dysfibrinogenemia › congenital afibrinogenemia › familial hypofibrinogenemia

Related subtypes (1): familial hypodysfibrinogenemia

Subtypes (1): hepatic fibrinogen storage disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 29 · Orphanet: 13 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
FGA	Supportive	Autosomal dominant	familial hypofibrinogenemia	14
FGB	Supportive	Autosomal dominant	familial hypofibrinogenemia	7
FGG	Supportive	Autosomal dominant	familial hypofibrinogenemia	8

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
FGA	Orphanet:101041	Familial hypofibrinogenemia
FGA	Orphanet:248408	Familial hypodysfibrinogenemia
FGA	Orphanet:93562	AFib amyloidosis
FGA	Orphanet:98880	Familial afibrinogenemia
FGA	Orphanet:98881	Familial dysfibrinogenemia
FGB	Orphanet:101041	Familial hypofibrinogenemia
FGB	Orphanet:248408	Familial hypodysfibrinogenemia
FGB	Orphanet:98880	Familial afibrinogenemia
FGB	Orphanet:98881	Familial dysfibrinogenemia
FGG	Orphanet:101041	Familial hypofibrinogenemia
FGG	Orphanet:248408	Familial hypodysfibrinogenemia
FGG	Orphanet:98880	Familial afibrinogenemia
FGG	Orphanet:98881	Familial dysfibrinogenemia

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
FGA	HGNC:3661	ENSG00000171560	P02671	Fibrinogen alpha chain	gencc
FGB	HGNC:3662	ENSG00000171564	P02675	Fibrinogen beta chain	gencc
FGG	HGNC:3694	ENSG00000171557	P02679	Fibrinogen gamma chain	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
FGA	Fibrinogen alpha chain	Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix.
FGB	Fibrinogen beta chain	Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix.
FGG	Fibrinogen gamma chain	Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	3	1.8×	0.174

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
FGA	Other/Unknown	no		Fibrinogen_a/b/g_C_dom, Fibrinogen_a/b/g_coil_dom, Fibrinogen_a/b/g_C_1
FGB	Other/Unknown	no		Fibrinogen_a/b/g_C_dom, Fibrinogen_a/b/g_coil_dom, Fibrinogen_a/b/g_C_1
FGG	Other/Unknown	no		Fibrinogen_a/b/g_C_dom, Fibrinogen_a/b/g_coil_dom, Fibrinogen_a/b/g_C_1

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
liver	3
right lobe of liver	3
type B pancreatic cell	2
islet of Langerhans	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
FGA	153	tissue_specific	marker	right lobe of liver, liver, islet of Langerhans
FGB	159	broad	marker	right lobe of liver, liver, type B pancreatic cell
FGG	157	broad	marker	right lobe of liver, liver, type B pancreatic cell

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
FGB	2,503
FGA	2,327
FGG	2,018

Intra-cohort edges

A	B	Sources
FGA	FGB	intact, string_interaction
FGA	FGG	biogrid_interaction, intact, string_interaction
FGB	FGG	biogrid_interaction, string_interaction

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
FGG	P02679	47
FGB	P02675	41
FGA	P02671	39

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 22. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Aggregated β-amyloid interacts with fibrinogen	3	2855.0×	4e-10	FGA, FGB, FGG
Fibrin formation	3	878.5×	1e-08	FGA, FGB, FGG
p130Cas linkage to MAPK signaling for integrins	3	761.3×	1e-08	FGA, FGB, FGG
GRB2:SOS provides linkage to MAPK signaling for Integrins	3	713.8×	1e-08	FGA, FGB, FGG
MyD88 deficiency (TLR2/4)	3	601.0×	2e-08	FGA, FGB, FGG
IRAK4 deficiency (TLR2/4)	3	571.0×	2e-08	FGA, FGB, FGG
Regulation of TLR by endogenous ligand	3	496.5×	2e-08	FGA, FGB, FGG
Integrin signaling	3	423.0×	3e-08	FGA, FGB, FGG
Signaling by high-kinase activity BRAF mutants	3	317.2×	7e-08	FGA, FGB, FGG
MAP2K and MAPK activation	3	285.5×	9e-08	FGA, FGB, FGG
Signaling by RAF1 mutants	3	278.5×	9e-08	FGA, FGB, FGG
Signaling by moderate kinase activity BRAF mutants	3	253.8×	9e-08	FGA, FGB, FGG
Paradoxical activation of RAF signaling by kinase inactive BRAF	3	253.8×	9e-08	FGA, FGB, FGG
Signaling downstream of RAS mutants	3	253.8×	9e-08	FGA, FGB, FGG
Signaling by BRAF and RAF1 fusions	3	170.4×	3e-07	FGA, FGB, FGG
MyD88:MAL(TIRAP) cascade initiated on plasma membrane	3	152.3×	4e-07	FGA, FGB, FGG
Integrin cell surface interactions	3	134.3×	5e-07	FGA, FGB, FGG
ER-Phagosome pathway	3	129.8×	5e-07	FGA, FGB, FGG
Platelet degranulation	3	87.8×	2e-06	FGA, FGB, FGG
Post-translational protein phosphorylation	2	66.8×	3e-04	FGA, FGG
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	2	57.7×	4e-04	FGA, FGG
Amyloid fiber formation	1	34.3×	0.029	FGA

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
blood coagulation, fibrin clot formation	3	1685.2×	2e-09	FGA, FGB, FGG
positive regulation of peptide hormone secretion	3	1532.0×	2e-09	FGA, FGB, FGG
plasminogen activation	3	1296.3×	2e-09	FGA, FGB, FGG
positive regulation of heterotypic cell-cell adhesion	3	1296.3×	2e-09	FGA, FGB, FGG
protein polymerization	3	991.3×	4e-09	FGA, FGB, FGG
fibrinolysis	3	842.6×	6e-09	FGA, FGB, FGG
positive regulation of vasoconstriction	3	601.9×	1e-08	FGA, FGB, FGG
positive regulation of exocytosis	3	601.9×	1e-08	FGA, FGB, FGG
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	3	581.1×	1e-08	FGA, FGB, FGG
negative regulation of endothelial cell apoptotic process	3	495.6×	2e-08	FGA, FGB, FGG
positive regulation of substrate adhesion-dependent cell spreading	3	374.5×	4e-08	FGA, FGB, FGG
positive regulation of protein secretion	3	343.9×	5e-08	FGA, FGB, FGG
platelet aggregation	3	337.0×	5e-08	FGA, FGB, FGG
response to calcium ion	3	318.0×	5e-08	FGA, FGB, FGG
cell-matrix adhesion	3	163.6×	4e-07	FGA, FGB, FGG
induction of bacterial agglutination	2	1872.4×	5e-07	FGA, FGB
protein-containing complex assembly	3	113.9×	9e-07	FGA, FGB, FGG
positive regulation of ERK1 and ERK2 cascade	3	85.1×	2e-06	FGA, FGB, FGG
blood coagulation, common pathway	1	2808.7×	4e-04	FGA
adaptive immune response	2	56.2×	5e-04	FGA, FGB
cellular response to leptin stimulus	1	510.7×	0.002	FGB
innate immune response	2	22.4×	0.003	FGA, FGB
cellular response to interleukin-1	1	93.6×	0.011	FGB
protein secretion	1	87.8×	0.011	FGG

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 1 · Undrugged: 2

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
FGB	1	2
FGA	0	0
FGG	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
SANGUINARIUM	2	FGB

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
FGB	2	Binding:2

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
SANGUINARIUM	2	FGB

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	1	FGB
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	FGA, FGG

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
FGA	0	FGB
FGG	0	FGB

Clinical trials & evidence

Clinical trials

Clinical trials: 0.